SCHEMBL2920097

SCHEMBL2920097

Cc1ccc(CN2CC(O)C2)cc1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.61
S1PR1 P21453 1/20 0.58
S1PR5 Q9H228 1/20 0.58
ALDH1A1 P00352 2/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
FUCA1 P04066 2/20 0.47
HRH4 Q9H3N8 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
BRD4 O60885 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
MAPK1 P28482 1/20 0.46
HRH1 P35367 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10272308 0.85 ALDH1A1 (0.57) GBA1ALDH1A1LMNAPOLBMEN1
SCHEMBL11841 0.85 ALDH1A1 (0.57) GBA1ALDH1A1LMNAPOLBMEN1
SCHEMBL13479261 0.85 ALDH1A1 (0.57) GBA1ALDH1A1LMNAPOLBMEN1
SCHEMBL20160542 0.83 ALDH1A1 (0.71) GBA1ALDH1A1LMNAPOLBL3MBTL1
SCHEMBL16121539 0.83 ALDH1A1 (0.71) GBA1ALDH1A1LMNAPOLBL3MBTL1
SCHEMBL21092815 0.82 GBA1 (0.63) GBA1S1PR1S1PR5ALDH1A1LMNA
SCHEMBL2918814 0.82 ALDH1A1 (0.53) S1PR1S1PR5ALDH1A1MEN1KMT2A
SCHEMBL18663826 0.81 GBA1 (0.48) GBA1S1PR1S1PR5ALDH1A1LMNA
SCHEMBL4700996 0.81 ALDH1A1 (0.60) ALDH1A1LMNAPOLBMEN1KMT2A
SCHEMBL3396517 0.80 GBA1 (0.61) GBA1S1PR1S1PR5ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
US-20100274003-A1 ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME Kukje Pharm Ind co. Ltd (KR) 2010-10-28 US disclosed
EP-1784407-B1 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF KOREA RES INST CHEM TECH (KR) 2010-09-08 EP disclosed
EP-2188287-A2 ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME Kukje Pharm. Ind. Co., Ltd. (KR) 2010-05-26 EP disclosed
US-7662810-B2 Potassium(1R,5S,6S)-2-(1-benzyl-azetidine-3-yl-thio)-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate; antibacterial activities against Grampositive and Gramnegative bacteria and excellent antibacterial activities against resistant bacteria such as methicillin resistant Staphylococcus aureus KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-16 US disclosed
CN-100494200-C 2-arylmethylazetidine carbapenem derivatives and preparation thereof KOREA RES INST CHEM TECH (KR) 2009-06-03 CN disclosed
WO-2009038328-A2 ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME KUKJE PHARM. IND. CO., LTD. (KR) 2009-03-26 WO disclosed
EP-1784407-A4 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF KOREA RES INST CHEM TECH (KR) 2009-02-11 EP disclosed
US-20070244089-A1 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-10-18 US disclosed
EP-1784407-A1 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF Korea Research Institute of Chemical Technology (KR) 2007-05-16 EP disclosed
CN-1946724-A 2-arylmethylazetidine carbapenem derivatives and preparation thereof KOREA RES INST CHEM TECH (KR) 2007-04-11 CN disclosed
WO-2006025634-A1 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100274003-A1 ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME SLC7A5, SI, ADSL GBA1 702/4885S1PR1 2879/4885S1PR5 1845/4885
US-20070244089-A1 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof SCN9A, SCN2A, SCN5A GBA1 1664/4885S1PR1 3950/4885S1PR5 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.